- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04664413
Percentage of BRAFV600E Alleles and Outcome in Thyroid Carcinoma (ABOUT)
Correlations Between Percentage of BRAFV600E Alleles and Outcome in Thyroid Carcinoma
BRAFV600E is the most frequent oncogene in Papillary thyroid carcinoma (PTC). It correlates with greater extension, lymph node metastasis, and advanced stage. However, the prognostic value of BRAFV600Eis weak and the search of this mutation is not recommended in clinical management of thyroid cancer.
PTC are characterized by intratumor heterogeneity with wild-type and BRAFV600E tumoral cells. In a previous study, the BRAFV600E/BRAFwild-type ratio correlated with patient age, tumor volume, lymph node metastasis and with worst disease outcome. While the existence of intratumor heterogeneity in PTC is supported by many evidences, its extension, biological significance and clinical utility is questioned and must be further investigated.
Primary endpoint of the study is to determine the relationship between the percentage of BRAFV600E alleles and outcome in PTC patients. Secondary endpoints are to determine the mean and median BRAFV600E/BRAFwild-type allele ratio in heterogeneous tumors; determine the relationship between the percentage of BRAFV600E alleles and clinicopathological features.
The study protocol entails the assessment by digital-droplet PCR the BRAFV600E/BRAFwild-type allele ratio in a series of PTC and its correlation with clinicopathology features and outcome.
Study Overview
Status
Conditions
Detailed Description
BACKGROUND Papillary thyroid carcinoma (PTC) generally shows an excellent prognosis with a 5-year survival of over 95%. Even when PTC metastasizes to the regional lymph nodes, a frequent occurrence, it generally has an excellent prognosis. However, there are some patients who present with an aggressive background or with specific clinicopathological features who exhibit aggressive developmental behavior. Several clinicopathological features, namely pathology subtype, age, distant and lymph node metastasis, extrathyroid extension, and completeness of resection can be used to predict prognosis and have been adopted in staging systems such as the AMES, MACIS, and AJCC TNM classifications.
The genetic background is a powerful prognostic determinant only when applied to some gene mutations such as TERT promoter and p53 mutations. The prognostic value of BRAFV600E, the most frequent oncogene in PTC, is weak. It correlates with greater extension, lymph node metastasis, and advanced stage (III/IV). Its correlation with outcome in PTC has been the object of many not always concordant studies. A large multicenter study was necessary to unequivocally demonstrate the association between BRAFV600E and cancer recurrence and mortality. The risk of PTC harboring BRAFV600E remains weak (recurrence hazard ratio 2.66) and the search of this mutation is not recommended in clinical management of low-risk patients with thyroid cancer.
Different research groups provided evidence on the heterogeneity of PTC that consist of a mixture of tumor cells with wild-type and BRAFV600E (5, 6). The importance of the percentage of BRAFV600E positive cells within the tumor was demonstrated in 168 PTC. The analysis of BRAFV600E/BRAFwild-type ratio was performed by pyrosequencing and higher ratio positively correlated with patient age, tumor volume, lymph node metastasis and with worst disease outcome. Patients with tumors with BRAFV600E/BRAFwild-type ratio ≥ 30% displayed an odds risk of tumor recurrence of 5.1, whereas it was only 1.75 in BRAFV600E positive tumors if the allele ratio was not considered. The qualitative analysis BRAFV600E positive versus negative PTC can explain the discordant correlations with clinicopathological features and outcome in different cohorts of patients with different ratio of BRAFV600E alleles, and ultimately the qualitative analysis BRAF mutational status can reduce the strength of its clinical significance and utility.
While the existence of intratumor heterogeneity in PTC is supported by many evidences, its extension, biological significance and clinical utility is questioned and must be further investigated.
Digital-droplet PCR (ddPCR) is an analytical method recently developed, suitable for absolute quantification of target DNA in a DNA mixture. It is the most accurate method to determine the BRAFV600E/BRAFwild-type allele ratio.
AIM OF THE RESEARCH
- Determine how frequent are subclonal-BRAFV600E PTC and to determine the mean and median BRAFV600E/BRAFwild-type allele ratio in heterogeneous tumors;
- Determine the relationship between the percentage of BRAFV600E alleles and clinicopathological features;
- Determine the relationship between the percentage of BRAFV600E alleles and outcome in PTC patients (primary endpoint)
STUDY DESIGN
- A large series of PTC formalin-fixed, paraffin-embedded (FFPE) tissues with a clinical follow up > 3 years will be analyzed by ddPCR to determine the percentage of BRAFV600E alleles.
- The purity of PTC samples and the ratio neoplastic cell/contaminating cells will be assessed by the a) analysis by rt-PCR of expression of a panel of RNA specific for lymphoreticular cells and stromal cells; b) microscopic review of adjoining tissue sections.
- Statistical analysis will be performed to search correlations between percentage of BRAFV600E alleles and a) pathology features, TNM, staging; b) recurrence and survival
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Salerno
-
Baronissi, Salerno, Italy, 84081
- Department of Medicine and Surgery, Univeristy of Salerno
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients undergone surgery because of any PTC subtypes 3 years before or more
- Availability of PTC tissue samples, well annotated
- Availability of clinical data of the patients including gender, age at diagnosis, type and extension of surgery, radiation therapy, radio-iodide therapy, TSH suppressive therapy
- Follow up of 3 years or more after surgery, including periodical 6 months assessment of TSH, thyroglobulin and AbTG, neck ultrasound evaluation and episodic hrTSH stimulation test
Exclusion Criteria:
- Inadequate tissue samples or clinical data and follow up
- Purity of PTC samples < 50%
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intratumor BRAFV600E heterogeneity and outcome
Time Frame: 6 months
|
3. Determine the relationship between the percentage of BRAFV600E alleles and outcome in PTC patients
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intratumor BRAFV600E heterogeneity quantification
Time Frame: 5 months
|
1. Determine how frequent are subclonal-BRAFV600E PTC and to determine the mean and median BRAFV600E/BRAFwild-type allele ratio in heterogeneous tumors
|
5 months
|
Intratumor BRAFV600E heterogeneity and clinicopathological features
Time Frame: 5 months
|
2. Determine the relationship between the percentage of BRAFV600E alleles and clinicopathological features
|
5 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Ito Y, Miyauchi A, Kihara M, Fukushima M, Higashiyama T, Miya A. Overall Survival of Papillary Thyroid Carcinoma Patients: A Single-Institution Long-Term Follow-Up of 5897 Patients. World J Surg. 2018 Mar;42(3):615-622. doi: 10.1007/s00268-018-4479-z.
- Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9. doi: 10.1210/jc.2005-0987. Epub 2005 Sep 20.
- Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Clifton-Bligh R, Tallini G, Holt EH, Sykorova V. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015 Jan 1;33(1):42-50. doi: 10.1200/JCO.2014.56.8253. Epub 2014 Oct 20.
- Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013 Apr 10;309(14):1493-501. doi: 10.1001/jama.2013.3190.
- Guerra A, Sapio MR, Marotta V, Campanile E, Rossi S, Forno I, Fugazzola L, Budillon A, Moccia T, Fenzi G, Vitale M. The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012 Feb;97(2):517-24. doi: 10.1210/jc.2011-0618. Epub 2011 Dec 14.
- Gandolfi G, Sancisi V, Torricelli F, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. J Clin Endocrinol Metab. 2013 May;98(5):E934-42. doi: 10.1210/jc.2012-3930. Epub 2013 Mar 26.
- Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I, Moccia T, Budillon A, Vitale M. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab. 2012 Jul;97(7):2333-40. doi: 10.1210/jc.2011-3106. Epub 2012 Apr 16.
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABOUT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Papillary Thyroid Cancer
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage II Papillary Thyroid Cancer | Stage III Papillary Thyroid Cancer | Stage I Papillary Thyroid CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI); GlaxoSmithKline; National Comprehensive Cancer...CompletedRecurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
National Cancer Institute (NCI)TerminatedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Anaplastic Thyroid Cancer | Stage III Follicular Thyroid Cancer | Stage III Papillary Thyroid CancerUnited States
-
University Health Network, TorontoUniversity of British Columbia; Canadian Institutes of Health Research (CIHR); CHU de Quebec-Universite Laval and other collaboratorsRecruitingPapillary Thyroid Carcinoma | Papillary Thyroid Cancer | Papillary Microcarcinoma of the ThyroidCanada
-
Mayo ClinicActive, not recruitingPapillary Thyroid Cancer | Papillary Thyroid MicrocarcinomaUnited States
-
National Cancer Institute (NCI)CompletedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid CancerUnited States
-
Massachusetts General HospitalCompletedPapillary Carcinoma of Thyroid Gland | Metastatic Medullary Thyroid Cancer | Follicular Thyroid Cancer Lymph Node MetastasisUnited States
-
Grupo Espanol de Tumores NeuroendocrinosMFARActive, not recruitingMetastatic Thyroid Cancer | Metastatic Thyroid Papillary Carcinoma | Metastatic Thyroid Follicular CarcinomaSpain
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid CancerUnited States